About Ventyx Biosciences
Ventyx Biosciences is a company based in Encinitas (United States) founded in 2018 by Raju Mohan was acquired by Lilly in January 2026. Ventyx Biosciences has raised $165.3 million across 4 funding rounds from investors including Lilly, Sanofi and Orbimed. The company has 82 employees as of December 31, 2024. Ventyx Biosciences offers products and services including VTX2735, VTX3232, Tamuzimod, and VTX958. Ventyx Biosciences operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Horizon Therapeutics and Ultragenyx, among others.
- Headquarter Encinitas, United States
- Employees 82 as on 31 Dec, 2024
- Founders Raju Mohan
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ventyx Biosciences, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$135.12 M (USD)29.97as on Dec 31, 2024
-
EBITDA
-$146.8 M (USD)28.23as on Dec 31, 2024
-
Total Equity Funding
$165.3 M (USD)
in 4 rounds
-
Latest Funding Round
$27 M (USD), Post-IPO
Sep 23, 2024
-
Investors
Lilly
& 15 more
-
Employee Count
82
as on Dec 31, 2024
-
Acquired by
Lilly
(Jan 07, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Ventyx Biosciences
Ventyx Biosciences is a publicly listed company on the NASDAQ with ticker symbol VTYX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Ventyx Biosciences
Ventyx Biosciences offers a comprehensive portfolio of products and services, including VTX2735, VTX3232, Tamuzimod, and VTX958.
Peripherally restricted inhibitor for treating recurrent pericarditis.
CNS-penetrant inhibitor for neurodegenerative and cardiometabolic diseases.
Modulator for inflammatory bowel disease management.
Inhibitor for inflammatory bowel disease treatment.
People of Ventyx Biosciences
Unlock access to complete
Unlock access to complete
Leadership Team
24 people
Product Management Team
8 people
Software Development Team
5 people
Advisor Team
4 people
Finance and Accounting
3 people
Data Analysis and Operations Team
2 people
Clinical Team
2 people
Chair Team
1 people
Unlock access to complete
Funding Insights of Ventyx Biosciences
Ventyx Biosciences has successfully raised a total of $165.3M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $27 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ventyx Biosciences
Ventyx Biosciences has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, Sanofi and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A life sciences investment firm focused on novel therapeutics is operated.
|
Locked | Locked | Locked | |
|
Life Sciences focused VC firm investing in the US
|
Locked | Locked | Locked | |
|
Multiple sectors are targeted for venture capital investments.
|
Locked | Locked | Locked |
Investor details for Ventyx Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ventyx Biosciences
Investment portfolio details for Ventyx Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ventyx Biosciences
Detailed financials for Ventyx Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ventyx Biosciences Comparisons
Peer comparison for Ventyx Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ventyx Biosciences
Ventyx Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Horizon Therapeutics and Ultragenyx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
Detailed competitors of Ventyx Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ventyx Biosciences
Complete news archive for Ventyx Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ventyx Biosciences
Ventyx Biosciences was founded in 2018 and raised its 1st funding round 3 years after it was founded.
Ventyx Biosciences is headquartered in Encinitas, United States. It is registered at Encinitas, California, United States.
Raju Mohan is the current CEO of Ventyx Biosciences. They have also founded this company.
Ventyx Biosciences is a funded company, having raised a total of $165.3M across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Ventyx Biosciences is 82.
Developer of therapeutics to treat autoimmune diseases. The companys pipeline drugs include VTX958 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002 S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735 peripheral inhibitor of the NLRP3 inflammasome. These drugs are used for the treatment of autoimmune disorders by regulating the innate and adaptive immunity to activate type 1 interferon, IL-12, and IL-23 signaling.
Ventyx Biosciences offers VTX2735, VTX3232, Tamuzimod, and VTX958.
Yes, Ventyx Biosciences is publicly traded on NASDAQ under the ticker symbol VTYX.
Ventyx Biosciences has 16 investors. Key investors include Lilly, Sanofi, Orbimed, Janus Henderson Investors, and RTW Investments.
The ticker symbol of Ventyx Biosciences is VTYX on NASDAQ.